As of 2026-09-02 02:46 UTC.Market figures are as the cited sources reported them at that time and may have moved since. This is news, not investment advice.
President Trump announced that nine additional drugmakers - Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB - have joined 17 earlier companies in pricing agreements aimed at lowering U.S. drug costs. [1]
Kyowa Kirin stock fell 11.1% to trade at ¥2,390 during the session on September 2, giving back all of the prior day's gains and more. [2] The stock decline occurred as the market digested the full implications of Kyowa Kirin's agreement with the Trump administration to lower drug prices in the U.S. Medicaid program. [3] Health Secretary Robert F. Kennedy Jr. said on Monday that nine out of ten drugs prescribed in the U.S. are now covered by the pricing deals. [4]
The nine new companies pledged to sell new medications at prices comparable to the lowest in peer countries, offer Medicaid 'most-favored nation' pricing, and in some cases bolster domestic manufacturing and contribute to U.S. medical stockpiles. [5] UCB, Sun Pharma, Teva, and Astellas will jointly contribute 290 metric tons of active pharmaceutical ingredients to the U.S. strategic reserves as part of the deals. [6] A majority of sell-side analysts covering the stock hold Sell or Underweight ratings, with consensus price targets sitting well below where the stock had been trading in recent weeks. [7]
The pricing arrangement is expanding to cover a broader list of pharmaceutical companies and products, raising concerns that mandated discounts could translate into material losses for Kyowa Kirin's North American business. [8]El presidente Trump anunció que nueve farmacéuticas adicionales, Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva y UCB, se han sumado a 17 empresas anteriores en acuerdos de precios destinados a reducir los costos de los medicamentos en EE. UU. [1]
Las acciones de Kyowa Kirin cayeron un 11.1% hasta cotizar en ¥2,390 durante la sesión del 2 de septiembre, devolviendo todas las ganancias del día anterior y más. [2] La caída de las acciones ocurrió mientras el mercado asimilaba todas las implicaciones del acuerdo de Kyowa Kirin con la administración Trump para reducir los precios de los medicamentos en el programa Medicaid de EE. UU. [3] El secretario de Salud, Robert F. Kennedy Jr., dijo el lunes que nueve de cada diez medicamentos recetados en EE. UU. están ahora cubiertos por los acuerdos de precios. [4]
Las nueve nuevas empresas se comprometieron a vender nuevos medicamentos a precios comparables a los más bajos de países pares, ofrecer precios de 'nación más favorecida' para Medicaid y, en algunos casos, reforzar la fabricación nacional y contribuir a las reservas médicas de EE. UU. [5] UCB, Sun Pharma, Teva y Astellas contribuirán conjuntamente con 290 toneladas métricas de ingredientes farmacéuticos activos a las reservas estratégicas de EE. UU. como parte de los acuerdos. [6] La mayoría de los analistas del lado vendedor que cubren la acción tienen calificaciones de Vender o Infraponderar, con precios objetivo de consenso muy por debajo de donde la acción había estado cotizando en las últimas semanas. [7]
El acuerdo de precios se está ampliando para cubrir una lista más amplia de empresas y productos farmacéuticos, lo que genera preocupación de que los descuentos obligatorios podrían traducirse en pérdidas significativas para el negocio de Kyowa Kirin en América del Norte. [8]
Proof8 sources · 2 publishers
What this stands on
President Trump announced that nine additional drugmakers - Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB - have joined 17 earlier companies in pricing agreements aimed at lowering U.S. drug costs. · STAT
Kyowa Kirin stock fell 11.1% to trade at ¥2,390 during the session on September 2, giving back all of the prior day's gains and more. · Investing.com
The stock decline occurred as the market digested the full implications of Kyowa Kirin's agreement with the Trump administration to lower drug prices in the U.S. Medicaid program. · Investing.com
Health Secretary Robert F. Kennedy Jr. said on Monday that nine out of ten drugs prescribed in the U.S. are now covered by the pricing deals. · STAT
The nine new companies pledged to sell new medications at prices comparable to the lowest in peer countries, offer Medicaid 'most-favored nation' pricing, and in some cases bolster domestic manufacturing and contribute to U.S. medical stockpiles. · STAT
UCB, Sun Pharma, Teva, and Astellas will jointly contribute 290 metric tons of active pharmaceutical ingredients to the U.S. strategic reserves as part of the deals. · STAT
A majority of sell-side analysts covering the stock hold Sell or Underweight ratings, with consensus price targets sitting well below where the stock had been trading in recent weeks. · Investing.com
The pricing arrangement is expanding to cover a broader list of pharmaceutical companies and products, raising concerns that mandated discounts could translate into material losses for Kyowa Kirin's North American business. · Investing.com
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Wednesday, September 2, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.